Skip to main content

Table 1 Patient characteristics before and after grouping by NTR

From: Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer

  

Cohort (n = 96)

Low-NTR (n = 44)

High-NTR (n = 52)

p-valueb

Gender

Male

88 (92%)

41 (93%)

47 (90%)

0.723

Female

8 (8%)

3 (7%)

5 (10%)

Age at diagnosisa

 

53.2 [49.0–58.5]

53.5 [48.9–59.6]

52.7 [49.0–58.2]

0.938

Previous cancer history

No

92 (96%)

42 (96%)

50 (96%)

1.000

Yes

4 (4%)

2 (5%)

2 (5%)

Performance status

ECOG 0–1

93 (97%)

41 (93%)

52 (100%)

0.093

ECOG 2–3

3 (3%)

3 (7%)

0 (0%)

Differentiation

Well to Moderate

68 (77%)

33 (83%)

35 (73%)

0.318

Poor

20 (23%)

7 (18%)

13 (27%)

Missing

8

4

4

Tumor lengtha(cm)

 

7.0 [5.7–8.4]

7.2 [5.6–9.0]

7.0 [5.8–8.0]

0.459

Tumor location

Cervical

22 (23%)

11 (25%)

11 (21%)

0.716

Upper third

31 (32%)

12 (27%)

19 (37%)

Middle third

40 (42%)

19 (43%)

21 (40%)

Lower third

3 (3%)

2 (5%)

1 (2%)

Nodal stage (AJCC 7th edition)

N0-N1

14 (15%)

9 (21%)

5 (10%)

0.028

N2

52 (54%)

27 (61%)

25 (48%)

N3

30 (31%)

8 (18%)

22 (42%)

First RT dosea(Gy)

<  40 Gy

45 (47%)

14 (32%)

31 (60%)

0.007

> = 40 Gy

51 (53%)

30 (68%)

21 (40%)

Chemotherapy regimen

Cisplatin + 5-FU

68 (71%)

28 (64%)

40 (77%)

0.064

Carboplatin + Paclitaxel

24 (25%)

12 (27%)

12 (23%)

Cisplatin + Paclitaxel

4 (4%)

4 (9%)

0 (0%)

SUVTumora

 

18.3 [14.8–23.2]

18.3 [15.6–24.4]

17.8 [13.3–21.7]

0.107

SUVLNa

 

9.2 [4.4–14.3]

4.4 [3.1–6.8]

13.7 [10.8–16.8]

< 0.001

NTRa

 

0.52 [0.24–0.80]

0.22 [0.13–0.31]

0.77 [0.65–0.98]

< 0.001

  1. SUVTumor maximal SUV of primary tumor, SUVLN maximal SUV of metastatic node, NTR node-to-tumor SUV ratio, 5-FU 5-fluorouracil
  2. a Values are presented as median [interquartile range, 25th–75th percentile]
  3. b Comparison of high-NTR and low-NTR groups, p values less than 0.05 indicated statistical significance